Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 9/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | WRN | Q14191 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4957720 | 0.83 | MGLL (0.37) | MGLLALDH1A1BLMNPSR1GMNN | |
| SCHEMBL3482678 | 0.83 | MGLL (0.39) | MGLLALDH1A1BLMNPSR1GMNN | |
| SCHEMBL28787286 | 0.82 | MGLL (0.45) | MGLLALDH1A1BLMNPSR1GMNN | |
| SCHEMBL9734841 | 0.79 | MGLL (0.37) | MGLLALDH1A1BLMNPSR1GMNN | |
| SCHEMBL2607935 | 0.78 | MGLL (0.39) | MGLLALDH1A1BLMNPSR1GMNN | |
| SCHEMBL7882002 | 0.72 | MGLL (0.46) | MGLLALDH1A1BLMNPSR1GMNN | |
| SCHEMBL1535518 | 0.72 | MGLL (0.46) | MGLLALDH1A1BLMNPSR1GMNN | |
| SCHEMBL28288544 | 0.71 | MGLL (0.37) | MGLLALDH1A1BLMNPSR1GMNN | |
| SCHEMBL209740 | 0.70 | MGLL (0.44) | MGLLALDH1A1BLMNPSR1GMNN | |
| SCHEMBL3863566 | 0.70 | MGLL (0.44) | MGLLALDH1A1BLMNPSR1GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120226022-A1 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | NEKTAR THERAPEUTICS (US) | 2012-09-06 | — | — | US | disclosed |
| US-8227555-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS (US) | 2012-07-24 | — | — | US | disclosed |
| US-20120123065-A1 | Hydrolytically Stable Maleimide-Terminated Polymers | NEKTAR THERAPEUTICS (US) | 2012-05-17 | — | — | US | disclosed |
| US-8106131-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS (US) | 2012-01-31 | — | — | US | disclosed |
| US-20090012241-A1 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-01-08 | — | — | US | disclosed |
| US-7432331-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432330-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120226022-A1 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | PADI6, MPI, VIM | MGLL 1012/4885ALDH1A1 1089/4885BLM 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.